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Risk factorsBackground: Long chain polyunsaturated fatty acid (PUFA) levels have been implicated in the pathology of psy-
chotic disorders. We investigated the relationship between childhood PUFA levels and later psychotic experi-
ences (PE's) in a large birth cohort.
Methods: Plasma levels ofΩ-3 andΩ-6 fatty acids (FA's) were assayed at ages 7 and 16 years. PE's were assessed
at ages 12 and 18 years using a semi-structured interview. Primary outcomewas any PE's at 18 years; sensitivity
analyses examined incident PE's between ages 12 and 18 years, persistent PE's (at 12 and 18) and psychotic dis-
order at 18 years. Genetic instruments forΩ-3 andΩ-6were derived and used in amultivariableMendelian Ran-
domization analysis.
Results: Higher levels ofΩ-6 FA's AA, OA and AdA at age 7 years were weakly associated with a reduced risk for
PE's at 18 years, however, effect sizes were small and attenuated after adjusting for confounders (strongest evi-
dence for OA; adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048). TotalΩ-6 levels at age 16 years were associated
with an increased odds of psychotic disorder at age 18 years. However, therewas no association betweenΩ-6/Ω-
3 ratio and psychosis outcomes, nor with genetic instruments of totalΩ-3 or Ω-6 levels.
Conclusions: There is no strong evidence that total plasmaΩ-3 FA levels orΩ-6/Ω-3 ratios in childhood andmid-
adolescence are associated with increased risk for PE's or psychotic disorder, but very marginal evidence that al-
terations in the Ω-6 pathway at developmental time points might influence risk2.
Crown Copyright © 2020 Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The role of nutritional factors in mental health has recently received
greater research focus (Sarris et al., 2015). A recent systematic review
reported a consistent trend across studies of a relationship between
good-quality diet and better child and adolescent mental health
(O'Neil et al., 2014), including commonpsychiatric disorders such as de-
pression and anxiety, but also psychotic disorders such as schizophre-
nia. An especially important nutrient group for brain development are
the essential fatty acids, including the long chain polyunsaturatednce in YouthMental Health, 35
. Thompson).
acid (trivial name adrenic acid;
e osbond acid; 22:5n-6).
r B.V. This is an open access article ufatty acids (PUFAs). Long chain PUFAs such as omega-3 are involved in
the neuromodulation of neurotransmitter uptake, degradation and syn-
thesis and receptor binding (Dyall, 2015; Liu et al., 2015). They also en-
hance cell membrane fluidity and neurogenesis via up regulation of
Brain-Derived Neurotrophic Factor (BDNF) (Mischoulon and Freeman,
2013). Omega-3 and omega-6 fatty acids also seem to have distinct
roles in the inflammatory pathway (Simopoulos, 2002), with omega-3
PUFAs such as docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) involved in the anti-inflammatory pathway, and omega-6
PUFAs such as arachidonic acid (AA) and docosapentaenoic acid (DPA)
appearing to be pro-inflammatory (Liu et al., 2015). The balance be-
tween omega-6 levels and omega-3 levels has been proposed to be im-
portant in a number of inflammatory diseases (Simopoulos, 2002). It
can be measured from dietary intake or biological measures and can
be calculated by the ratio of mean n-6 and n-3 fatty acid levels
(Sheppard and Cheatham, 2013) or of total levels (Thesing et al.,
2018). Inflammatory processes have long been proposed as ander the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ported by evidence from clinical studies of microglial activation
(Cannon, 2016), and epidemiological studies of prenatal and childhood
infections (Karlsson and Dalman, 2020), autoimmune disorders
(Jeppesen and Benros, 2019), and proinflammatory cytokines
(Momtazmanesh et al., 2019).
PUFA abnormalities have been found in a number of studieswith pa-
tients with psychotic disorders. Low levels of omega-3 (and omega-6)
fatty acids have also been found in the red cell membranes of patients
with schizophrenia (Peet et al., 1995), although this is not consistent
across all studies (Medema et al., 2016). Associations between psychotic
symptoms and lowered levels of some omega-3 (Docosapentaenoic
acid, DPA) and 6 fatty acids (γ-linolenic and docosadienoic acids) in
red cell membranes have been found in “at risk for psychosis” groups
(Kim et al., 2016). Omega-6/omega-3 dietary intake, possibly reflecting
the balance between neuroprotective and proinflammatory pathways,
is also altered in both first episode psychosis and those presenting
with clinical high risk for psychosis (Pawełczyk et al., 2017). A causal
role of PUFA's in development of schizophrenia is supported by a trial
that demonstrated a beneficial effect of relatively high dose omega-3
supplementation (750 mg EPA/DHA) on risk of transition to psychosis
in a clinical high risk for psychosis sample(Amminger et al., 2010). A
more recent replication trial did not demonstrate an significant overall
effect (McGorry et al., 2017), however, increases of the n-3 index, EPA,
and DHA in this trial predicted less severe psychopathology and better
functioning (Amminger et al., 2020). The same group found that PUFA
supplementation in a clinical high risk groupmay act by normalizing in-
tracellular phospholipase A2 activity and δ-6-desaturase-mediated me-
tabolism of omega-3 and omega-6 PUFAs (Smesny et al., 2014). The
researchers hypothesized that omega-3 fatty acid supplementation
had an effect on cell membrane stability and, through this and other
pathways, acted as a neuroprotector (Amminger et al., 2015).
If levels of PUFA's are altered in patients at risk for psychosis and pre-
dict transition to psychosis, then it would be useful to investigate levels of
long chain PUFA's in childhood to investigate whether levels or ratio dif-
ferences at an early age are psychosis risk factors. Cohort studies are the
strongest observational study design for investigating the effects of
PUFA levels on development of psychopathology, including psychotic dis-
order. As psychotic disorder is a relatively rare outcome, the presence of
psychotic experiences, especially if persistent or associated with impair-
ment, may be a good proxy for psychosis risk. Clinically diagnosed psy-
chosis has a lifetime prevalence of around 3% (Perala et al., 2007), but
psychotic experiences and sub-clinical expressions are estimated to
occur in approximately 7.5–17% of the general population (Kelleher
et al., 2012a; Zammit et al., 2013). This broader spectrum of psychosis
can also result in significant distress, functional impairment, increased
suicidal behaviour (Kelleher et al., 2012b) and increases the risk of devel-
oping a full-blown psychotic disorder in adulthood (Fisher et al., 2013;
van Os et al., 1999) especially in individuals whose psychotic experiences
persist over time (Dominguez et al., 2011; Kaymaz et al., 2012).
One study in a large cohort of Swedishwomen aged 30–49 found that
the intake of fatty acids at baseline (as measured by a food frequency
questionnaire) was related to the levels of self-reported psychotic experi-
ences a decade later (Hedelin et al., 2010). This was the case for both
omega-3 and omega-6 dietary fatty acid levels, but the relationship was
non-linear and a high fatty acid intake level was also associated with an
increased risk of psychotic experiences as well as low levels. This study
was in an older population, with potential for residual confounding and
used a dietary questionnaire, not biological levels, thus being prone to
measurement error (Hedelin et al., 2010). There have been no reports in-
vestigating childhood PUFA levels and psychotic experiences.
To address some of these issues we aimed to investigate the associ-
ation between childhood blood levels of omega-3 and omega-6 fatty
acids levels and late adolescent risk of developing psychotic experiences
and other psychosis outcomes including psychotic disorder in a large
birth cohort. This included investigating genetic proxies of these levels109using Mendelian Randomization to address residual confounding and
reverse causation. We specifically hypothesized that an altered
omega-6/omega-3 ratio in childhood would be associated with an in-
crease in late adolescent psychotic experiences.
2. Methods
2.1. Participants
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a
UK birth cohort study (Boyd et al., 2013; Fraser et al., 2013). Pregnant
women resident in Avon District with an expected delivery date be-
tween 1st April 1991 and 31st December 1992 were approached to
participate in the study, leading to the inclusion of 14,775 live births
with 14,701 of these alive at 1 year of age. This analysis is based on
4720 children who completed the Psychosis-LIKe Symptoms interview
(PLIKSi) at approximately 18 years of age. Ethical approval for the
study was obtained from the ALSPAC Ethics and Law Committee and
the Local Research Ethics Committees (http://www.bristol.ac.uk/
alspac/researchers/research-ethics/). Consent for biological samples
has been collected in accordancewith the Human Tissue Act (2004). In-
formed consent for the use of data collected via questionnaires and
clinics was obtained from participants following the recommendations
of the ALSPAC Ethics and Law Committee at the time.
2.2. Outcome variables
2.2.1. Primary outcome
2.2.1.1. Psychotic experiences. The PLIKSi (Horwood et al., 2008; Zammit
et al., 2013) is a semi-structured face-to-face interview, rated according
to guidelines for the Schedules for Clinical Assessment in Neuropsychi-
atry version 2.0 (SCAN2.0), which elicits key psychotic experiences cov-
ering hallucinations (visual and auditory), delusions (spied on,
persecution, thoughts read, reference, control, grandiosity and other un-
specified delusions), and experiences of thought interference (thought
broadcasting, insertion and withdrawal). The PLIKS interview was car-
ried out in the cohort at the age of 12 and the age of 18. The average
kappa values for inter-rater and test-retest reliability were 0.83 and
0.76 at the age of 18 (Zammit et al., 2013). Further detail on the instru-
ment is available elsewhere (Zammit et al., 2013) as well as further de-
tail on this data (Horwood et al., 2008; Zammit et al., 2013). The primary
outcomewas ≥1 of the PLIKSi experiences suspected or definitely present
at age 18 and not attributable to sleep, fever or substance use.
2.2.2. Sensitivity analyses
We also examined three other psychosis outcomes, including some
that are potentially more clinically meaningful but less common.
These were: a) at least 1 suspected or definite psychotic experience in-
cident by age 18 (i.e. not present at 12), b) at least 1 suspected or defi-
nite psychotic experience present at both age 12 and age 18 (persistent
PLIKS), and c) psychotic disorder at age 18. We classified individuals as
having a psychotic disorder if they reported definite psychotic experi-
ences not attributable to the effects of sleep or fever that had occurred
at least once per month over the previous 6 months and either caused
severe distress, had a markedly negative impact on social or occupa-
tional function, or led to help seeking (see Zammit et al., 2013).
2.3. Independent variables
2.3.1. Omega-3/6 PUFA levels
Overall plasma PUFA levels and levels of individual omega-3 and
omega-6 fatty acids were available from non-fasting blood samples
taken from the children at mean 7.5 years (5576). From these samples,
plasmawas obtained after centrifugal separation and frozen immediately.
All sampleswere stored at−70 °C, thawed once to obtain a 100 μl aliquot,
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for analysis. Transmethylation of lipidswith acetyl chloride andmethanol
was performed using a simplified method based on the Lepage and Roy
procedure (Lepage and Roy, 1986) using a high throughput automated
method (Masood and Salem, 2007). Internal calibration was conducted
by adding internal standards to each assay. A second standard was used
to quantify the exact amount of internal standard in every batch for ongo-
ing assay of experimental variability. Freedom Evo Instrument 200
(TECAN Trading AG, Switzerland) was utilised for the automatic
transmethylation and extraction of fatty acids employing the customised
control and automation software (EVOware V.2.0, SP1, Patch3). Gas chro-
matography 6890 Plus LAN system (Agilent Technologies, Inc., Santa
Clara, California, USA) coupled with a fused-silica, narrow-bored DB-
FFAP capillary column (Agilent 127-32H2, 15 m × 0.1 mm ID×0.1 μm
film thickness) which was used for chromatographic separation of the
fatty acid methyl esters as reported previously (Masood and Salem,
2007). The assay was linear in the range of 1–600 μg/ml plasma. The
within and between day imprecision was 3.26 ± 1.2% and 2.95 ± 1.6%
for fatty acid concentrations. Assays were undertaken in 2009–2010. In
all, 23 FAs were measured including 12 polyunsaturates (Golding et al.,
2012).
Summary fatty acids levels and some specific individual fatty acids
(DHA and LA) were also measured at age 16 years using a high-
throughput Nuclear Magnetic Resonance (NMR) metabolomics platform
(Soininen et al., 2015; Soininen et al., 2009). Metabolite data were
assessed on fasting (minimum 6-h) plasma. All fatty acid levels were
expressed as percentage of total fatty acids and standardized before
analyses.
A summary of the available fatty acidmeasures are shown in Table 1
and the omega-3 and omega-6 metabolic pathways are shown in Fig. 1.
2.4. Genetic data
Following quality control assessment and imputation, genetic data
was available for 8252 ALSPAC individuals. For further information on
the genetic data please refer to the online Supplementary methods.
2.4.1. Fatty acid genetic instruments
Due to competition for the same elongases and desaturases during
omega-6 and omega-3 PUFA biosynthesis, it is difficult to disentangle
the specific effects of omega-3 from omega-6 on an outcome. One ap-
proach that can be used to attempt to overcome this is by using genetic
instruments for omega-3 and omega-6 FA levels within a multivariableTable 1
Omega 3 (n-3) and omega 6 (n-6) fatty acids measures available in ALSPAC at ages 7 and
16 years.
Measure (as % of total fatty
acids)
Age
7 years 16 years












Note: LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic
acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial
name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA,α-linolenic
acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic
acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3
fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.
110analysis. This method, known as MultiVariable Mendelian Randomiza-
tion (MVMR), is an extension of single exposureMendelian randomiza-
tion whereby genetic variants that reliably predict one exposure
variable, but do not influence the outcome through any other pathway,
are used as instrumental variables in estimating the true causal effect of
the exposure on the outcome (Davey Smith and Hemani, 2014).
Genetic instrumentswere derived using summary statistics from the
recentKettunen et al. (2016)meta-analysis of genome-wide association
studies (GWAS) of blood levels of DHA, LA, total omega-3 and total
omega-6 fatty acidsmeasured using a high-throughput NMRmetabolo-
mics platform in up to 24,925 individuals (Kettunen et al., 2016). Based
on the GWAS meta-analysis summary statistics, a list of SNPs that were
associated with total omega-3 and total omega-6 fatty acid levels at a
genome-wide level of significance (p value ≤5e−8) was extracted. Fur-
ther information on the genetic instruments please refer to the online
Supplementary methods and Supplementary Table 1.
2.5. Confounders
For the non-genetic analyses, the following confounders were able
to be considered due to their potential influence on the exposure and
outcome: Gender; Ethnic group; Highest Parental Social Class; Maternal
Education (A levels/degree or equivalent (higher education) v O-level/
CSE's (Certificate of Secondary Education - lowest UK school-leaving
qualifications)); BirthWeight; Family Adversity Index (FAI)multiple fam-
ily risk factors were assessed during pregnancy with the Family Adver-
sity Index (Bowen et al., 2005); Body Mass Index (BMI) at 7 and at
16 years (The child's BMI was calculated at the same clinic when the
blood sample were taken for the FA analysis); Energy intake at 7 and at
13 years (The child's overall energy intakewas calculated from the com-
pletion of the Food Frequency Questionnaire as part of the interview
ages 7 and 13 years). Please see Supplementary methods for further de-
tails of confounders and Supplementary Table 2 for number of individ-
uals with available data on each confounder and the proportion who
also had available psychotic experience data.
2.6. Statistical analyses
2.6.1. Observational analyses
Logistic regression was performed to assess the association between
fatty acid plasma levels in ALSPAC at age 7 and age 16 years and psy-
chotic experiences outcomes at age 18 years. Results are presented for
unadjusted and adjusted analyses, where potential confounders have
been included as covariates within the logistic regression.We addition-
ally tested the associations between each genetic instrumental variable
for omega-3 and omega-6 FA fatty acid levels in ASLPAC and psychotic
experiences at age 18 years using logistic regression. All statistical anal-
yses were performed using Stata (Version 15.1; StataCorp LP, College
Station, TX, USA).
2.6.2. Mendelian randomization
A two-stage least squares MVMRwas implemented using the ivreg2
(Baum et al., 2002) command in STATA v14.2 with robust standard er-
rors. The strength of the instrumental variables used in the analysis
was assessed using the Sanderson-Windmeijer conditional F test of ex-
cluded instruments (Sanderson and Windmeijer, 2016) which tests if
the genetic instruments strongly and jointly predict both exposures in
the outcome model. Genetic instruments with an F-statistic of 10 or
less are generally deemed to be weak.
3. Results
3.1. Description of the sample
The frequencies of psychotic experiences in the cohort and in those
with PUFA data are shown in Table 2. Rates were similar in those with
Fig. 1. Omega 3 and Omega 6 metabolic pathway (from Calder, 2017).
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at 7 and 16 years are shown in Supplementary Table 3. PUFA levels
were available for 5565 children at age 7 years and 3356–3360 children
at age 16 years.3.2. Association of PUFA plasma levels at 7 years and psychotic experiences
at 18 years
In the unadjusted analyses there was weak evidence that higher
levels of omega-6 AA, AdA and OA were associated with a decreased
odds of psychotic experiences at age 18 years (AA: odds ratio (OR),
0.853; 95% confidence interval (CI), 0.728, 0.999; p, 0.049; AdA: OR,
0.826; 95% CI, 0.702, 0.972; p, 0.021; OA: OR, 0.822; 95% CI, 0.697,
0.970; p, 0.020). The CI included the null for all but one of the adjusted
associations between fatty acid levels at age 7 years (OA) and psychotic
experiences at age 18 years (OA: adjusted OR, 0.842; 95% CI, 0.711,
0.998; p, 0.048) (see Table 3).3.3. Association of fatty acids blood levels at 16 years and psychotic experi-
ences at 18 years
In the unadjusted analyses higher DHA levelswere associatedwith a
decreased risk of psychotic experiences (OR, 0.871; 95% CI 0.736, 1.032;
p, 0.110) but the CI's include the null and this was further attenuated
when adjusted for potential confounders (see Table 4).3.4. Sensitivity analyses
We performed sensitivity analyses examining different psychosis
outcomes including more stringent/clinically-relevant psychosis out-
comes. When the outcome excluded those who reported psychotic ex-
periences at age 12 years, (incident psychotic experiences) an
association was seen for higher levels of omega-6 AA, AdA and OA and
there was weak evidence that lower AA:EPA ratio at age 7 years in-
creased the odds of reporting psychotic experiences (Supplementary
Table 4). Higher LA and total omega-6 levels at age 16 years were asso-
ciatedwith an increased odds of psychotic disorder at age 18 years,with
evidence slightly weakening in the adjusted analysis, especially for LA
(Supplementary Table 5).1113.5. Association of fatty acids genetic instruments and psychotic experiences
The allelic scores (weighted and unweighted) acted as stronger in-
struments for total omega-3 and total omega-6 fatty acid measures at
age 16 years than using the individuals SNPs as instruments (Table 5);
however, no Sanderson-Windmeijer F-statistic exceeded 10 indicating
that the genetic instruments were weak. There was no strong evidence
that instrumental variables for levels of omega-3 or omega-6were asso-
ciated with psychotic experiences at 18 years of age, nor the other sec-
ondary psychosis outcomes (Table 5 and Supplementary Table 6).
4. Discussion
The study aimed to investigate the association between childhood
plasma levels of long chain PUFAs and development of psychotic expe-
riences in late adolescence. Overall, omega-3 and omega-6 fatty acids
levels taken at 7 and 16 years were not strongly associated with any
of the psychotic outcomes examined. When examining our primary
outcome, there was weak evidence that higher levels of the omega-6
fatty acid OA and AdA at age 7 years were associated with a decreased
risk of psychotic experiences but only the OA association survived ad-
justment of confounders and effect sizes were small. When examining
other psychosis outcomes, there was stronger evidence of association
between OA, AdA and also AA at age 7 years, and of a higher AA
(omega-6):EPA (omega-3) ratio at this age, with reduced risk of inci-
dent psychotic experiences between ages 12 and 18 years. There was
also very weak evidence that total omega-6 fatty acid levels at
16 years were associated with increased risk of psychotic disorder. In
the Mendelian randomization analysis there was no evidence of associ-
ation between GWAS-based instrumental variables for total omega-3
and omega-6 levels and psychotic experiences at 18 years.
The majority of studies in patients with established psychosis have
found a reduction in PUFA levels, especially DHA, DPA and AA (Hoen
et al., 2013). Authors have suggested that these results could be second-
ary to antipsychotic treatment although some studies have found re-
duced levels in antipsychotic naive patients (Reddy et al., 2004).
However, it is unclear if these PUFA changes in these populations with
an established psychotic disorder reflect a propensity to poorer re-
sponse to inflammation or even an early response to inflammation or
a marker of oxidative stress. Cohort studies or studies in at risk groups
are therefore key to try to disentangle these effects but there is very lim-
ited data on PUFA levels in patients prior to the onset of psychosis or
psychotic experiences. The only cohort study in the extant literature of
Table 2
Prevalence of psychotic experiences at age 18 years.
Psychotic experience measure N N (%) with
PE








Definite/suspected versus none 4718 432 (9.16) 2844 229 (8.05) 2465 208 (8.44)
Incident psychotic experiences versus nonea 3513 205 (5.84) 2308 140 (6.07) 1981 110 (5.55)
Persistent psychotic experiences versus noneb 4058 134 (3.30) 2631 61 (2.32) 2299 77 (3.35)
Psychotic disorder versus nonec 4718 79 (1.67) 2844 43 (1.51) 2465 38 (1.54)
a Denotes individuals with definite or suspected psychotic experiences at age 18 years and no definite or suspected psychotic experiences at age 12 years.
b Denotes individuals with definite or suspected psychotic experiences at age 12 years and age 18 years.
c Psychotic disorder defined by psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either
caused severe distress, had a markedly negative impact on social or occupational function, or led to help seeking.
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6 as measured by dietary intake were associated with a reduced risk of
later psychotic experiences (Hedelin et al., 2010). The associationswere
reverse J-shapedwith the strongest reduced risk for an intermediate in-
take of fish or PUFA (Hedelin et al., 2010).
In our study, there was no evidence that higher plasma levels of the
omega-3 PUFADHA in late adolescencemay be protective against broad
psychotic experiences. However, whilst higher levels of a number
omega-6 PUFAs in childhood appeared to be protective against psy-
chotic experiences, we also found in our sensitivity analyses that higher
levels of omega-6 PUFAs in adolescence appeared to increase the risk for
developing a psychotic disorder. These findings are not consistent with
the suggestion that overactivity of the pro-inflammatory omega-6 path-
way may be propsychotic and overactivity of the anti-inflammatory
omega-3 pathway may be antipsychotic (Amminger et al., 2010), al-
though the structure of the omega-6/omega-3 pathways suggests that
relationships of these PUFAs with psychopathologymay be highly com-
plex and that studying their ratiomay bemore informative. The omega-
6/omega-3 plasma ratio (expressed through dietary levels) that has
been reported to be altered/elevated in patients at risk for psychosis
(Pawełczyk et al., 2017) compared to healthy controls, was not associ-
ated with the psychosis outcomes in our study.
There are a number of possible explanations for this. Firstly, PUFA
levels may be differentially important at specific periods of develop-
ment. For example, any potential neuroprotective balance of omega-6/
omega-3 PUFAs might be particularly important in guarding against
psychosis risk in the adolescent brain when synaptic pruning is occur-
ring in brain areas believed to be key in psychosis, such as the prefrontal
cortex and limbic structures. This could also be why omega-3 fatty acid
supplementation may be relatively more effective in younger at-riskTable 3
Unadjusted and adjusted association between fatty acid measures at age 7 years and psychotic
Outcome Exposure Unadjusted
OR (95% CIs)
Definite/suspected psychotic experiences versus none
LA 0.993 (0.851, 1
AA 0.853 (0.728, 0
AdA 0.826 (0.702, 0
OA 0.822 (0.697, 0
Total n6 0.938 (0.805, 1
ALA 1.043 (0.896, 1
EPA 0.997 (0.853, 1
DPA 0.982 (0.841, 1
DHA 0.978 (0.841, 1
Total n3 0.996 (0.855, 1
AA:EPA 0.890 (0.758, 1
n6:n3 0.968 (0.828, 1
Note: OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence
experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, d
acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; A
docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels
fatty acids.
a Adjusted for gender; ethnic group; highest parental social class;maternal education; birthw
112groups than in populations with established psychosis, who are gener-
ally older.
Secondly, it could be that any early dysfunction in PUFAmetabolism
is actually located in different places in the pathway and later deficien-
cies represent a potential compensatory or downstream effect. The
omega-6 and omega-3 pathways are not independent of each other
and any enzyme deficiency or dietary deficiency will have an effect on
other parts of the pathway. This is the reason why we chose not to
look at individual PUFA levels in our MR approach but examined the
overall effects of the pathways using total levels.
Thirdly, the plasma levels at ages 7 and 16 years weremeasured dif-
ferently, with levels at age 16 years taken after 6 h fasting and levels at
age 7 years non-fasting. We are also aware that we have only examined
PUFA levels in isolation and these differences might represent the
downstream effect of other overlapping processes such as eicosanoids
and other inflammatory pathways. For example, a previous study in
this cohort reported higher levels of inflammatory cytokines Interleukin
6 and C Reactive Protein to be related to psychosis (Khandaker et al.,
2014), and there are a number of other factors that influence these
pathways (Horrobin et al., 1994). We also did not examine omega 9
PUFA levels, as these were not available in the cohort. More research
is needed into the interplay between PUFA levels, PUFA metabolism,
pro and anti-inflammatory eicosanoids and other inflammatory pro-
teins and risk for developing psychotic symptoms and psychotic
disorder.
The results of the MR approach also did not demonstrate any clear
associations between these genetic proxies of PUFA levels and psychotic
experiences. This leads us to havemore certainty that there is not a clear
relationship that is confounded by a factor we were not able to adjust
for. MR is a useful tool in areas where there are clear genetic variantsexperiences at age 18 years.
Adjusteda N N (%) with PE
P OR (95% CIs) P
.159) 0.931 1.001 (0.856, 1.172) 0.986
2310 174 (7.53)
.999) 0.049 0.873 (0.742, 1.026) 0.100
.972) 0.021 0.855 (0.723, 1.012) 0.068
.970) 0.020 0.842 (0.711, 0.998) 0.048
.094) 0.415 0.954 (0.817, 1.114) 0.553
.214) 0.586 1.038 (0.891, 1.210) 0.633
.164) 0.967 0.987 (0.843, 1.156) 0.871
.146) 0.813 0.995 (0.848, 1.167) 0.948
.139) 0.776 1.016 (0.871, 1.186) 0.835
.160) 0.956 1.020 (0.874, 1.191) 0.803
.044) 0.152 0.912 (0.777, 1.072) 0.265
.132) 0.688 0.956 (0.813, 1.124) 0.585
interval; P, p-value for association between fatty acid levels at age 7 years and psychotic
ocosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic
LA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3
of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3
eight; family adversity index, bodymass index at age 7 years; energy intake at age 7 years.
Table 4
Unadjusted and adjusted association between fatty acid measures at age 16 years and psychotic experiences at age 18 years.
Outcome Exposure Unadjusted Adjusteda N N (%) with PE
OR (95% CIs) P OR (95% CIs) P
Definite/suspected psychotic experiences versus none
LA 1.001 (0.850, 1.180) 0.990 0.991 (0.840, 1.170) 0.917
1974 159 (8.05)
Total n6 0.944 (0.802, 1.111) 0.488 0.938 (0.797, 1.106) 0.447
DHA 0.871 (0.736, 1.032) 0.110 0.882 (0.740, 1.051) 0.162
Total n3 0.918 (0.779, 1.083) 0.312 0.946 (0.799, 1.120) 0.518
n6:n3 1.080 (0.926, 1.259) 0.330 1.050 (0.895, 1.231) 0.550
Note: OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence interval; P, p-value for association between fatty acid levels at age 16 years and psychotic
experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic
acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3
docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3
fatty acids.
a Adjusted for gender; ethnic group; highest parental social class; maternal education; birth weight; family adversity index, body mass index at age 16 years; energy intake at age
13 years.
A.D. Thompson, H.J. Jones, J. Heron et al. Schizophrenia Research 224 (2020) 108–115in biological pathways (Davey Smith and Hemani, 2014). We have ex-
amined overview levels of total PUFA levels in isolation in this MR anal-
ysis and not specific omega 3 FAs such as EPA or DHA that are used in
supplementation, nor omega-6/omega-3 ratios.4.1. Strengths and limitations
The strengths of the research are the large dataset, the robust mea-
surements both of psychotic experiences and PUFA levels (at 2 time
points), and the ability to adjust formultiple confounders. There is likely
to be no or veryminimal antipsychotic use prior to themeasure of PLIKS
at 18 years (this is a non-clinical population). We have also performed
anMR analysis to attempt to specifically address unspecified confound-
ing and reverse causation effects.
Although the sample size is large, there is a considerable amount of
missing data from the original cohort and there are relatively small
numbers for some of the secondary psychosis outcomes, meaning the
results for these outcomes should be interpreted with this caveat. For
secondary outcomes such as psychotic disorder that sample is still
below the expected age of peak incidence. There a number of other po-
tential confounders such as cannabis use, cigarette smoking and child-
hood trauma as well as information on dietary supplementation and
other general nutritional factors that were not adjusted for. The num-
bers are also relatively small for the MR analysis.
The use of plasma fatty acid levels and not red blood cell membrane
(RBC) levels or brain cell membrane levels is also a potential weakness.
Themembrane hypothesis of schizophrenia posits that there are poten-
tial alterations in the cell membrane structure (Horrobin, 1999;
Horrobin et al., 1994) and we are unable to examine this in this cohort.
Although there is often considerable correlation between plasma PUFATable 5
Multivariable Mendelian randomization results showing associations between total
omega-3 and omega-6 fatty acids at age 16 years and definite/suspected psychotic expe-
riences at age 18 years.
Exposure N OR (LCI, UCI) P SW F SW F P
Instruments = unweighted allele scores
Total omega-3 1922 1.14 (0.83, 1.57) 0.421 8.41 0.004
Total omega-6 0.91 (0.75, 1.10) 0.326 2.39 0.122
Instruments = weighted allele scores
Total omega-3 1922 1.17 (0.82, 1.68) 0.384 6.94 0.009
Total omega-6 0.91 (0.77, 1.09) 0.307 2.73 0.099
Instruments = individual SNPs
Total omega-3 543 1.04 (0.84, 1.30) 0.698 0.96 0.511
Total omega-6 1.00 (0.95, 1.05) 0.904 1.26 0.206
Note: OR, odds ratio; LCI, lower 95% confidence level; UCI, upper 95% confidence level; SW,
Sanderson-Windmeijer conditional F test of excluded instruments.
113levels and thosemeasured in RBCmembranes (Sun et al., 2007), plasma
levels are more sensitive to fluctuations in diet and recent intake
whereas RBC levels reflect long term fatty acid intake (Harris and
Thomas, 2010). There are some measures of RBC PUFA's in the ALSPAC
cohort although the sample with data is small (just over 500) and the
samples were of cord blood and may be mixed fetal and maternal sam-
ples; therefore, a meaningful analysis was not possible. It is also neces-
sary to mention that the assays used to measure PUFA levels differ by
age (gas chromatography at 7 years vs. NMR at 16 years). Although
units were standardized before analyses, the sensitivity of gas chroma-
tography is superior to NMR. The PUFA levels at 7 years were also non-
fasting as opposed to the levels at 16 years being6 h fasting.Wenote the
MR analysis is likely to give a longer-term proxy of FA levels as an inter-
mediate variable that is not susceptible to fluctuation in diet and intake.
We have also not measured eicosanoid levels in this analysis and how
these relate to the PUFA levels.
4.2. Clinical implications
There is no clear evidence of specific alterations in PUFAmetabolism
prior to the onset of psychotic symptoms or psychotic disorder in our
findings. If PUFA's are protective against psychosis inset, any potential
mechanism of protection and the timing of any protection remains un-
clear or whether changes seen in psychosis risk samples are a conse-
quence of pathological processes in a psychotic state; the results of
current and ongoing trials in at risk for psychosis subjects (Kane and
Correll, 2017) may shed further light on this.
4.3. Conclusions
In this cohort study did not find evidence of childhood PUFA levels
being strongly associatedwith psychotic experiences and other psycho-
sis outcomes in late adolescence. This may reflect that alterations may
be a state phenomena or a timing issue with levels being especially im-
portant during times when brain inflammatory and anti-inflammatory
processes are key.
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